Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
NCT05364645 · SWOG Cancer Research Network · PHASE2 · withdrawn · last registry update 2024-07-09 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of accrual” | Open Targets' class: insufficient enrollment | Registry record, SWOG Cancer Research Network |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against RET in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-13Results posted on the registry: Massachusetts General Hospital, Alectinib + Bevacizumab (NCT02521051)
- 2025-05-13Also stopped (terminated): Massachusetts General Hospital, Alectinib + Bevacizumab (NCT02521051)
- 2025-03-26Results posted on the registry: ETOP IBCSG Partners Foundation, Alectinib (NCT03445000)
- 2025-02-19Results posted on the registry: Takeda, Brigatinib + Alectinib (NCT03596866)
- 2025-01-09Phase 3 first posted: Nuvalent Inc., Neladalkib (NVL-655) + Alectinib (NCT06765109)
- 2024-10-02Phase 3 first posted: Hoffmann-La Roche, Alectinib + Cisplatin (NCT06624059)
- 2024-08-26Results posted on the registry: Hoffmann-La Roche, Alectnib + Cisplatin (NCT03456076)
- 2024-06-20Results posted on the registry: Eli Lilly and Company, Selpercatinib + Carboplatin (NCT04194944)
- 2023-11-21Results posted on the registry: National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2023-08-14Phase 3 first posted: Medicine Invention Design, Inc, ALECENSA - alectinib hydrochloride capsule (NCT05987956)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision